Delivery Order SPE2DB22D1017-SPE2DB25FG9GL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Restasis 0.05% eye emulsion (30 count) at a firm fixed price of $1,117.80. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of August 4, 2025, with performance to be completed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,318.51 on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (30 single-use vials). This firm fixed price delivery order, with an ultimate completion date of July 29, 2025, represents a small-value transaction issued under a larger indefinite delivery contract vehicle. The award was made through competitive procurement with no set-aside designation, and the product will be delivered to...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a $1,117.68 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $28,637.24 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RESTASIS 0.05% Eye Emulsion in 60-count units. This is a competitively awarded, firm fixed-price delivery order valued at $1,862.70 with no set-aside designation, with an ultimate completion date of July 23, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,444.74 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on August 7, 2025, with completion targeted for August 8, 2025. This is a firm fixed-price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $3,169.04 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9GLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Restasis 0.05% Eye Emulsion in quantities of 30 units, with a firm fixed price ceiling value of $2,716.92. This is a non-set-aside award with an ultimate completion date of August 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive pharmaceutical supply relationship with DLA, which serves the military and veteran healthcare systems. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive vehicle enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare operations globally. AmerisourceBergen's continued selection for DLA pharmaceutical requirements reflects its capability to meet federal procurement standards through competitive award processes and deliver specialized medical commodities across multiple therapeutic domains to support Department of Defense healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/8/25 |